UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: CATB |
| Industry | Pharmaceuticals |
| Headquarters | Cambridge, Massachusetts |
|
Key people
|
Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer and Senior Vice President, Clinical Development) Ted Hibben (Chief Business Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer) |
| Products | Orally-delivered pharmaceuticals |
|
Number of employees
|
34 (June 2015) |
| Website | www.catabasis.com |
Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer and Senior Vice President, Clinical Development) Ted Hibben (Chief Business Officer)
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. Catabasis’ SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables the company to engineer molecules that simultaneously modulate multiple targets in a disease. Catabasis is applying their SMART linker platform to build an internal pipeline of product candidates for rare diseases and plans to pursue partnerships to develop additional product candidates.
| 2016-06-09 | Lower Price Target | Citigroup Inc. | Buy | $16.00 to $8.00 |
| 2016-06-08 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-06-07 | Reiterated Rating | Wedbush | Outperform | $27.00 to $17.00 |
| 2016-05-25 | Reiterated Rating | Oppenheimer | Outperform | $28.00 |
| 2016-05-25 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | $28.00 |
| 2016-05-14 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-14 | Reiterated Rating | Oppenheimer | Buy | |
| 2016-05-13 | Reiterated Rating | Wedbush | Outperform | $27.00 |
| 2016-03-28 | Reiterated Rating | Wedbush | Outperform | $27.00 |
| 2016-03-22 | Lower Price Target | Citigroup Inc. | Buy | $21.00 to $16.00 |
| 2016-03-07 | Reiterated Rating | Cowen and Company | Outperform | $30.00 |
| 2016-03-02 | Reiterated Rating | Wedbush | Outperform | $27.00 |
| 2016-01-19 | Reiterated Rating | Wedbush | Outperform | $27.00 |
| 2016-01-04 | Reiterated Rating | Wedbush | Outperform | $27.00 |
| 2015-12-11 | Initiated Coverage | Wedbush | Buy | |
| 2015-12-10 | Reiterated Rating | Wedbush | Outperform | $27.00 |
| 2015-08-17 | Reiterated Rating | Wedbush | Buy | $27.00 |
| 2015-07-20 | Initiated Coverage | Oppenheimer | Positive to Outperform | $28.00 |
| 2015-07-20 | Initiated Coverage | Citigroup Inc. | Buy | $21.00 |
| 2015-07-20 | Initiated Coverage | Cowen and Company | Outperform | $30.00 |
| 2015-07-20 | Initiated Coverage | Wedbush | Outperform | $27.00 |
| 2016-06-09 | Lower Price Target | Citigroup Inc. | Buy | $16.00 to $8.00 |
| 2016-06-08 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-06-07 | Reiterated Rating | Wedbush | Outperform | $27.00 to $17.00 |
| 2016-05-25 | Reiterated Rating | Oppenheimer | Outperform | $28.00 |
| 2016-05-25 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | $28.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CATB 6 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Clarus Ventures, LLC | 2.01M |
| KCG Holdings, Inc. | 0.19M |
| Jump Trading, LLC | 23573 |
| BlackRock Fund Advisors | 18108 |
| BlackRock Investment Management, LLC | 1024 |
| LADENBURG THALMANN FINANCIAL SERVICES INC | 120 |
UM